I need some sales if I'm going to stay in business. Please place orders via the affiliate links on this web site. It's the same price. If you bookmark or type in the URL, I don't get credit for the sale.

QualityCounts.com Comprehensive Anti-aging Research

Home

iHerb

Int Antiaging Sys

Prescriptions

Life Extension Products

Amazon.com

Dr. Weil's Vitamin Advisor

Contact

Welcome to the Quality Counts. For those health conscious consumers and medical professionals that are looking to purchase nutritional supplements, vitamins, herbs, learning about medications, losing weight, health food, low carbs, high protein nutrition, and exercise, you have come to the right place. Quality Counts serves both the medical practitioner and consumer interested in nutritional therapy and alternative medicine.

Home > Health Conditions > Breast Cancer > Arimidex

Arimidex (anastrozole) - 9/00

Related Topics:

Where to purchase:

Aromatization (in males):

Anastrozole (Arimidex) - anabolic-androgenic-steroids.com - "Anastrozole (Arimidex) is the aromatase inhibitor of choice" - see aromatization

Aromatase Inhibition Offers Little Benefit, Possible Harm to Men With Lo... - Medscape, 12/22/09 - "The inescapable conclusion from these data is that the 50% increase in testosterone levels was trumped by the much more modest 20% reduction in estradiol levels, leading to negative skeletal effects of anastrozole therapy in aging men" - Note: I'm not sure that thought this though thoroughly. Mortally in men is best when estrogen is around 25pg/mL. I suspect that most have higher estrogen than that. See:

High, Low Estradiol Levels and Mortality in Men With Systolic HF - Medscape, 5/19/09 - "Both low and high serum levels of estradiol, compared with mid-range levels, are significantly and independently associated with increased all-cause mortality in men with chronic systolic heart failure"
Serum Estradiol Concentration Quintiles as Predictors of All-Cause Mortality in Men (With Quintile 3 as the Reference Group)

Parameter	Quintile 1	Quintile 2	Quintile 3	Quintile 4	Quintile 5
Estradiol concentration (pg/mL)	<12.903	12.90–21.79	21.80–30.11	30.12–37.39	>37.40
3-y survival* (%)	44.6	65.8	82.4	79.0	63.6
Quintile as mortality predictor,* HR (95% CI) vs quintile 3	4.17 (2.33–7.45)	2.15 (1.16–3.99)	--	1.22 (0.64–2.31)	2.33 (1.30–4.18)

HR= hazard ratio

Ibandronate Can Prevent Anastrozole-Induced Bone Loss - Medscape, 6/6/07
Drug Combination May Slow Male Breast Cancer Growth - Science Daily, 7/7/06
Testosterone Deficiency & Depression, Does DHEA Raise the Levels of Bioavailable Testosterone in Men? - Life Extension Magazine, 8/02 - "Some men on testosterone drug replacement therapy develop dangerously high estrogen levels. Estrogen can be suppressed by taking an aromatase-inhibiting drug like Arimidex (0.5 mg twice a week) or using a supplement like Super Mira Forte (six capsules daily)"
Male Hormone Modulation Therapy - Life Extension Magazine - "If all of the above fail to increase free testosterone and lower excess estradiol, then ask your doctor to prescribe the potent aromatase inhibiting drug Arimidex (anastrozole) in the very low dose of one-half (0.5 mg) mg, twice a week"
Estrogen suppression in males: metabolic effects - J Clin Endocrinol Metab. 2001 Apr;86(4):1836-8 - "First, a dose-response study of 12 males (mean age, 16.1 +/- 0.3 yr) was conducted, and blood withdrawn at baseline and after 10 days of oral Arimidex given as two different doses (either 0.5 or 1 mg) in random order with a 14-day washout in between. A sensitive estradiol (E2) assay showed an approximately 50% decrease in E2 concentrations with either of the two doses ... There was a 58% increase in serum T"

CME:

Aromatase Inhibitors in Breast Cancer: An Update - The University of South Florida College of Medicine, exp. 12/1/03

News & Research:

Joint Supplements for Aromatase Inhibitor Adverse Effects - Medscape, 11/18/11 - "Aromatase inhibitors are widely used in the treatment of breast cancer but are associated with significant musculoskeletal adverse effects, including joint pain and stiffness ... We know that these symptoms are unresponsive to conventional pain medication and often lead to low adherence to aromatase inhibitor therapy ... The cohort consisted of postmenopausal breast cancer patents with stage I to III disease who had been on aromatase therapy for at least 3 months, who reported a pain rating of 4 or higher on a 10-point visual analog scale, and whose pain worsened after initiating treatment with aromatase inhibitors if they had preexisting osteoarthritis ... Participants took 1500 mg/day of glucosamine and 1200 mg/day of chondroitin, and were evaluated every 6 weeks at the clinic ... There was a drop in pain and stiffness in the hips and knees at 12 and 24 weeks, as well as improvement in function. "This affected about 50% of the women," she explained. "We saw a very similar pattern looking at the hands and the wrist. We saw similar results with the Brief Pain/Stiffness Inventory — with about 35% to 50% of women."" - See glucosamine products at iHerb and chondroitin products at iHerb.
Toxicity of aromatase inhibitors may explain lack of overall survival improvement - Science Daily, 8/22/11 - "compared to tamoxifen, longer use of AIs was associated with increased heart disease and bone fractures, but lower rates of blood clots and cancer of the womb. There were no differences in the risk of stroke or other types of cancer. Furthermore, use of AIs for 2-3 years after initial treatment with tamoxifen was associated with a lower risk of death unrelated to breast cancer compared to the use of either AIs or tamoxifen alone. The authors therefore concluded that the toxicity of AIs when used for longer periods of treatment may explain the lack of overall survival benefit while still having a positive effect on breast cancer recurrence"
Vitamin D relieves joint, muscle pain for breast cancer patients - Science Daily, 7/26/11 - "Rastelli's group recruited 60 patients who reported pain and discomfort associated with anastrozole, one of three FDA-approved aromatase inhibitors. The patients they studied also had low vitamin D levels. Half the group was randomly assigned to receive the recommended daily dose of vitamin D (400 international units) plus a 50,000-unit vitamin D capsule once a week. The other half received the daily dose of 400 units of vitamin D plus a weekly placebo. All subjects received 1,000 milligrams of calcium daily throughout the study ... patients receiving high-dose vitamin D every week reported significantly less musculoskeletal pain and also were less likely to experience pain that interfered with daily living" - See vitamin D products at iHerb.
Anastrozole Accelerates Bone Loss - Medscape, 3/18/08 - "Anastrozole-treated women experienced a decrease in median BMD from baseline to 5 years in the lumbar spine (-6.08%) and total hip (-7.24). Tamoxifen-treated women had an increase in median BMD over the 5-year period in lumbar spine (+2.77%) and total hip (+0.74%)"
Anastrozole's Superiority in Preventing Recurrence Confirmed In 100-Month ATAC Follow-Up - oncologystat.com, 12/20/07
Vitamin D Supplementation Reduces Fatigue and Muscle Pain in Women With Early-Stage Breast Cancer - Doctor's Guide, 12/17/07 - "Treatment of low levels of vitamin D in women with early stage breast cancer appears to reduce fatigue and muscle pain associated with aromatase inhibitor therapy" - See vitamin D products at iHerb.
Breast Cancer: Arimedex vs. Tamoxifen - WebMD, 12/14/07
Extended Adjuvant Aromatase Inhibitor Therapy Beneficial in Breast Cancer - Medscape, 12/11/07 - "Women with breast cancer who complete 5 years of tamoxifen therapy derive significant benefit from an additional 3 years of treatment with the aromatase inhibitor anastrozole"
Pain Makes Some End Breast Cancer Drug - WebMD, 9/6/07 - "23% of the women in the new study given one of two aromatase inhibitors -- Aromasin or Femara -- stopped taking their drugs due to side effects, which also included hot flashes and nausea ... Forty-two percent of the women reported serious bone and joint problems, such as severe pain or difficulty opening a jar, and were referred for evaluation by a rheumatologist"
Anastrozole Less Likely to Cause Venous Thromboembolism Than Tamoxifen - Doctor's Guide, 12/19/06
Drug Switch Ups Breast Cancer Survival - WebMD, 11/17/06
Women With Early Breast Cancer are More Likely to Remain Cancer Free by Changing Treatment From Tamoxifen to Anastrozole - Doctor's Guide, 11/17/06
Aromatase Inhibitors Declared Superior to Tamoxifen in the Adjuvant Treatment of Early Breast Cancer - Doctor's Guide, 8/1/06
Five Years on Anastrozole Can Promote Progression to Osteoporosis - Medscape, 6/12/06 - "Women taking anastrozole also had about a 40% increased risk of fractures while on the study ... At 5 years, women taking anastrozole lost 6.1% of BMD at the hip and 7.2% at the spine ... women with a normal BMD at baseline did not develop osteoporosis"
Patients Who Switch From Tamoxifen to Anastrozole Have Longer Survival and Time to Progression - Doctor's Guide, 6/4/06
Bone Loss Associated with Aromatase Inhibitor Therapy for Breast Cancer Confirmed - Doctor's Guide, 6/4/06 - "Aromatase inhibitor use was associated with a relative risk (RR) ratio of 1.3"
Neoadjuvant Aromatase Inhibitors May Be as Effective as Chemotherapy in Locally Advanced Breast Cancer - Doctor's Guide, 3/27/06
Five-Year Data from Austrian Trial Shows Significant Benefit in Switching From Tamoxifen to Anastrozole - Doctor's Guide, 12/14/05
No Differences in Time to Response for Fulvestrant and Anastrozole in Advanced Breast Cancer Patients - Doctor's Guide, 12/13/05
Survival Advantage of Anastrozole over Tamoxifen Seen in Meta Analysis - Doctor's Guide, 12/12/05
Fewer Gynecological Problems Seen in Women on Anastrozole in ATAC Study - Doctor's Guide, 12/12/05
Long-term Consequences of the Aromatase Inhibitors - Medscape, 11/16/05 - "The "short-term toxicities," such as vasomotor symptoms, venothromboemboli, and gynecologic complications, favor the use of AIs. However, long-term bone loss, altered lipid profiles, and possible compromise in sexual functioning appear to be adversely affected by the AIs"
Anastrozole Has Better Risk:Benefit Profile than Tamoxifen for Breast Cancer Patients - Doctor's Guide, 11/2/05
Aromatase Inhibitors Have Different Cardiovascular Safety Profiles - Doctor's Guide, 11/2/05
Arimidex (Anastrozole) Gains Full FDA Approval for Adjuvant Treatment of Hormone Receptor-Positive Early Breast Cancer in Postmenopausal Women - Doctor's Guide, 9/20/05
Arimidex (Anastrozole) Granted New Indication Enabling Wider Access for Postmenopausal Women With Breast Cancer - Doctor's Guide, 6/28/05
Long-Term Use of Anastrozole Shows Benefits in Women Who Have Completed Tamoxifen Therapy - Doctor's Guide, 5/213/05
Anastrozole for 6 Months Aids Breast Conservation in Older Women - Doctor's Guide, 3/4/05
5 Years of Adjuvant Treatment With Anastrozole (Arimidex) Shows Better Results Than Tamoxifen in Breast Cancer - Doctor's Guide, 2/2/05
Women With Hormone-Sensitive Early Breast Cancer Benefit from Switch to Anastrozole After 2 Years Adjuvant Tamoxifen - Doctor's Guide, 1/31/05
Trials Support Replacing Tamoxifen With Anastrozole at Two Years - Medscape, 12/9/04
Anastrozole Continues to Show Benefits Over Tamoxifen - Doctor's Guide, 12/9/04
Arimidex (Anastrozole) Appears Superior to Tamoxifen in Reducing Breast Cancer Recurrence - Doctor's Guide, 12/9/04
Arimidex Beats Gold Standard Tamoxifen - WebMD, 12/8/04
Emerging Successes of Aromatase Inhibitor Switching Trials Likely to Influence Practice Patterns, Future Trials - Doctor's Guide, 7/29/04
Benefits of Aromatase Inhibitors Should Outweigh Physicians' Concerns About Long-Term Toxicity Issues - Doctor's Guide, 7/29/04
Aromatase Inhibitors Still Superior Over Tamoxifen, but Questions Remain About Estrogen Receptor Factors - Doctor's Guide, 7/27/04
New Aromatase Inhibitors Similarly Effective Despite Differences in Oestrogen Suppression - Doctor's Guide, 6/30/04
Neoadjuvant Therapy With Anastrozole Doubles Rate of Surgical Downstaging from Mammography to Lumpectomy - Doctor's Guide, 4/29/04
Anastrozole Might Have Superior Tolerability Profile Compared to Tamoxifen - Doctor's Guide, 4/29/04
Study Suggests Anastrozole Fracture Risk Stabilizes Over Time - Doctor's Guide, 4/29/04
Fulvestrant Appears Comparable to Anastrozole Therapies for Treatment of Hormone Receptor-Positive Metastatic Breast Cancer - Doctor's Guide, 4/29/04
Anastrozole Potentially More Effective Than Tamoxifen Against Hormone-Sensitive Breast Cancer - Doctor's Guide, 3/23/04
Anastrozole Protective Against Endometrial Cancer - Doctor's Guide, 3/22/04
Anastrozole vs. Tamoxifen: Risk of Bone Loss Outweighed By Tolerability in Early Breast-Cancer Therapy - Doctor's Guide, 3/22/04
Goserelin and Anastrozole as Second-Line Endocrine Therapy in Premenopausal Breast Cancer Patients Appears Safe, Effective - Doctor's Guide, 3/9/04
Anastrozole Shows Promise for Breast Cancer Chemoprevention - Doctor's Guide, 2/17/04
Molecular Marker Finds Newer Hormonal Therapy Slows Tumor Growth More - Doctor's Guide, 12/5/03
Pre-Surgical Hormonal Therapy With Aromatase Inhibitor May Shrink More Breast Tumors - Doctor's Guide, 12/4/03
Arimidex Helps Shrink Breast Cancer Tumors - WebMD, 12/4/03
Anastrozole Replaces Adjuvant Tamoxifen - Medscape, 12/4/03
Neoadjuvant Anastrozole Reduces Need for Mastectomy - Medscape, 12/3/03
Drug Switch Staves Off Breast Cancer - WebMD, 12/3/03
Benefits of Anastrozole Outweigh Risk of Bone Fractures Compared with Tamoxifen - Doctor's Guide, 9/29/03
Worries Lessen Over New Breast Cancer Drug - HealthDay, 9/26/03
Fracture Risk With Anastrozole Levels off in Postmenopausal Women - Medscape, 9/23/03
Fracture Risk with Anastrozole (Arimidex) Stops Increasing After Two Years of Treatment - Doctor's Guide, 8/6/03
Fulvestrant (Faslodex) Demonstrates Non-inferiority to Anastrozole in Advanced Hormone-Sensitive Breast Cancer - Doctor's Guide, 8/5/03
Anastrozole (Arimidex) Shows Efficacy and Safety in Receptor-positive Breast Cancer - Doctor's Guide, 4/14/03
Anastrozole Extends Overall Survival Compared to Tamoxifen in Postmenopausal Breast Cancer - Doctor's Guide, 2/6/03
Anastrozole Effective for Advanced Ovarian, Peritoneal and Fallopian Tube Carcinomas - Doctor's Guide, 2/4/03
Anastrozole Superior to Tamoxifen as Adjuvant Treatment in Early Breast Cancer - Medscape, 12/13/02
Anastrozole-Tamoxifen Sequence Best for Advanced Breast Cancer - Doctor's Guide, 12/13/02
Arimidex (Anastrozole) Continues to Show Benefits Over Tamoxifen in Early-stage Breast Cancer - Doctor's Guide, 12/12/02
Arimidex Better Than Tamoxifen Long Term - WebMD, 12/11/02
New Treatment Options in Advanced Breast Cancer - Medscape, 12/11/02 - "A double-blind crossover trial showed that anastrozole (ARI) should be given as first-line adjuvant therapy with tamoxifen (TAM) used after first progression for women with advanced breast cancer"
Anastrozole Superior to Tamoxifen in Early Post-menopausal Breast Cancer - Doctor's Guide, 10/21/02
Anastrozole is Better Than Tamoxifen for Treatment of Postmenopausal Women with Advanced Breast Cancer - Doctor's Guide, 10/21/02
Anastrozole Could Be Associated with Fewer Endometrial Abnormalities than Tamoxifen in Early Breast Cancer - Doctor's Guide, 10/19/02
Astrazeneca Granted U.S. Approval For Arimidex (Anastrozole) In Early Breast Cancer - Doctor's Guide, 9/6/02
Fulvestrant as Effective as Anastrozole in Breast Cancer - Medscape, 8/19/02
Anastrozole An Option For Postmenopausal Hormone-Sensitive Early Breast Cancer - Doctor's Guide, 6/21/02
Breast Cancer Drug [Arimidex] Continues to Shine - WebMD, 6/20/02
Letrozole Produces Better Response than Anastrozole in Advanced Breast Cancer - Doctor's Guide, 5/22/02
Head-To-Head Worldwide Study Of The Two Leading Aromatase Inhibitors Shows More Women Respond To Femara (Letrozole) Than Arimidex (Anastrozole) In Advanced Breast Cancer - Doctor's Guide, 5/21/02
Study Reports on Endometrial Changes Comparing Tamoxifen With Arimidex (Anastrazole) in Postmenopausal Women Treated for Early Breast Cancer - Doctor's Guide, 5/21/02
New Breast Cancer Drug [Arimidex] Tops Tamoxifen - WebMD, 3/27/02
Arimidex (Anastrozole) Agent of Choice for Future Chemoprevention/Risk Reduction Studies in Breast Cancer - Doctor's Guide, 2/15/02
Femara (Letrozole) More Effective Than Arimidex (Anastrozole) at Inhibiting Estrogen in Advanced Breast Cancer - Doctor's Guide, 1/31/02
FDA Grants Fast-Track Status to Arimidex (Anastrozole) for Early Breast Cancer - Doctor's Guide, 1/14/02
Anastrozole (Arimidex) Outperforms Tamoxifen and Combination in Adjuvant Breast Cancer - Doctor's Guide, 12/11/01
Improved Clinical Outcomes With Anastrozole In Advanced Breast Cancer With Visceral Metastases - Doctor's Guide, 10/24/01
Single Monthly Injections with Faslodex (Fulvestrant) as Effective as Anastrazole in Post-Menopausal Advanced Breast Cancer - Doctor's Guide, 11/1/01
Arimidex (Anastrozole) Shown to be Gold Standard for Advanced Breast Cancer - Doctor's Guide, 10/19/01
Arimidex (Anastrozole) Followed By Tamoxifen Highly Effective For Advanced Breast Cancer - Doctor's Guide, 9/19/01
Anti-Aromatase Agents Cost-Effective For Women With Metastatic Breast Cancer - Doctor's Guide, 5/15/01
Arimidex Reinforced As A First-Line Choice For Patients With Aggressive Metastatic Breast Cancer - Doctor's Guide, 5/12/01
Better Survival With Arimidex (Anastrozole) Than Tamoxifen In Postmenopausal Women With Advanced Breast Cancer - Doctor's Guide, 12/11/00
First-Line Anastrozole Effective Against Advanced Breast Cancer After Tamoxifen - Doctor's Guide, 12/8/00
Faslodext (ICI182,780) At Least As Effective As Arimidex (Anastrozole) In Advanced Breast Cancer - Doctor's Guide, 12/7/00
Arimidex (Anastrozole) First-Line Therapy Highly Effective For Advanced Breast Cancer - Doctor's Guide, 9/28/00
FDA Approves Arimidex (Anastrozole) For Hormone Receptive Advanced Breast Cancer - Doctor's Guide, 9/5/00
Neoadjuvant Therapy With Hormones May Avoid Some Mastectomies in Post-Menopausal Women - Doctor's Guide, 6/6/00
Anastrozole May Replace Tamoxifen In Postmenopausal Breast Cancer - Doctor's Guide, 2/1/00
Arimidex More Effective Than Nolvadex For Advanced Breast Cancer - Doctor's Guide, 12/10/99
Anastrozole As Effective As Tamoxifen For Advanced Breast Cancer In Postmenopausal Women - Doctor's Guide, 9/15/99
Zeneca Receives FDA Clearance for Arimidex to Treat Breast Cancer - Doctor's Guide, 1/31/96

Abstracts:

Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer - J Clin Oncol. 2008 Apr 1;26(10):1671-6 - "Letrozole reduces plasma E2 and E1S levels to a significantly greater extent than anastrozole" - See Femara (letrozole) at OffshoreRX.
Anastrozole Increases Predicted Adult Height of short adolescent males treated with growth hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years - J Clin Endocrinol Metab. 2007 Dec 28 - "Anastrozole increases adult height potential of adolescent boys on GH therapy while maintaining normal pubertal progression after 2-3 yrs. This treatment offers an alternative in promoting growth in GH deficient boys in puberty"
Memory impairments with adjuvant anastrozole versus Tamoxifen in women with early-stage breast cancer - Menopause. 2007 Sep 25 - "The results showed that women who received anastrozole had poorer verbal and visual learning and memory than women who received tamoxifen"